StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.12−0.06 (-2.75%)

Close on Nov 19, 2026Market cap $101.23MP/E –Yield –

Minerva Neurosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2022 it was -$24.66M, down 911.1% from the year before.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$24.66M-911.1%
FY2017Dec 31, 2017$3.04M–
FY2014Dec 31, 2014-$36.01M–
FY2013Dec 31, 2013-$2.16M–

More Minerva Neurosciences figures

See a number that looks wrong?